🇮🇹 Save the date: TRANSCAN-3 JTC 2023 symposium in Milan on Oct 28–29. 👥 Projects, workshops, training & more — especially for early career researchers.

📌EPILUNAR is one of the 13 projects funded by the 2023 TRANSCAN-3 JTC and is aimed at discovering novel biomarkers to identify mNSCLC patients who will benefit from immune checkpoint inhibitors (ICIs). Click here to know more about the project 👉 https://t.co/whWiOtFC4s

EPILUCAFS is one of the 13 projects funded by the 2023 TRANSCAN-3 JTC and is aimed at investigatin how chronic inflammation related to psychosocial stress shapes the tumour microenvironment and tumour draining lymph nodes in lung cancer. To know more 👉 https://t.co/Y8yxfUbxAX

EPI_T-ALL is one of the 13 projects funded by the 2023 TRANSCAN-3 JTC and is aimed at characterizing critical molecular events that drive the progression of human T-cell progenitors from normal to outright malignant states. To know more 👉 https://t.co/DH6PKZG06o

DICE is one of the 13 projects funded by the 2023 TRANSCAN-3 JTC, and it aims to untangle the epigenomic impact of dietary intervention (namely anti- inflammatory diet, AID) for the identification of new epigenetic therapeutic targets. To know more 👉 https://t.co/oZseEMRsEv

📚 Last 10 and 11 October, the SEC for the Transcan-3 JTC 2024 gathered in Catania for the pre-proposal evaluation of JTC 2024 of TRANSCAN-3. 💡 Today, the Funders will decide, based on the ranking list, how many proposals will advance to the second stage.

DC2M-TAEC is one of the 13 projects funded by the 2023 TRANSCAN-3 JTC, and it aims to develop a platform to simultaneously generate methylation and sequencing results. Click here to know more 👉 https://t.co/aRAxvuPisp

Today is World Cancer Research Day, an event that aims to promote global collaboration for cancer research and to increase survival, facilitate access to scientific advances worldwide, and reduce the global burden of cancer. Learn about our commitment 👉 https://t.co/3YQnTlru3d

The first Meeting of the SEC for the Transcan-3 JTC 2024 is approaching! On October 10th - 11th, 2024, we will celebrate our second Symposium in Catania, Italy, featuring the projects of our call JTC 2022 and the evaluation of pre-proposals of our latest call JTC 2024.

📢 The Transcan-3 JTC 2023 has successfully concluded, selecting 13 consortia for funding, with an allocation of almost 17 million euros dedicated to advancing translational research on cancer epigenetics. Discover the awarded projects on our website 👉 https://t.co/NxohEqQgHd

❞𝗡𝗲𝘄 𝗙𝗿𝗼𝗻𝘁𝗶𝗲𝗿𝘀 𝗶𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗜𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆❞, organized by ISI and SITC, is set to take place on 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟭𝘀𝘁, prior to the 7th European Congress of Immunology (ECI) in Dublin, Ireland. To register:

📣 𝗧𝗖𝟯 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝘀 𝘁𝗵𝗮𝘁 𝘁𝗵𝗲 𝟯𝗿𝗱 𝗝𝗼𝗶𝗻𝘁 𝗧𝗿𝗮𝗻𝘀𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗮𝗹𝗹 𝗳𝗼𝗿 𝗣𝗿𝗼𝗽𝗼𝘀𝗮𝗹𝘀 𝟮𝟬𝟮𝟰 (𝗝𝗧𝗖 𝟮𝟬𝟮𝟰) 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗹𝗮𝘂𝗻𝗰𝗵𝗲𝗱 𝗶𝗻 𝗔𝗽𝗿𝗶𝗹 𝟮𝟬𝟮𝟰❗ Visit the website for all details:

Don't forget to subscribe to Transcan-3 newsletter here:  https://t.co/xI6Uka9eqI It is the best way to stay updated on news, events and funding opportunities, such as the upcoming JTC2024. Stay tuned! #cancer #oncology #research

We would like to start the new year sharing with you all the successful story of a project funded by TRANSCAN-2. The project INTRACOLOR has discovered new potentially targetable alterations for a molecular subpopulation of methastatic CRC (mCRC) patients.

🎄 We are getting close to Christmas and we would like to wish you all happy and relaxing days and a pleasant end of this year... But, most important: a great start of 2024! 🎉 The next year we will come back with fresh news on the 𝘂𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝗝𝗧𝗖𝟮𝟬𝟮𝟰, so stay tuned!

The 6th edition of our newsletter is officially out: enjoy reading!

Do you want to stay updated on Transcan-3 activities, news and funding opportunities? Subscribe to our newsletter here: https://t.co/xI6Uka9eqI The next newsletter will be published in December, so stay tuned! #cancer #oncology #research

𝗦𝗜𝗠𝗠𝗕𝗔𝗣 project will study the interactions between local mechanisms of tumorigenesis and the host’s systemic immunity to uncover mechanisms, non-invasive biomarkers and actionable targets to improve early detection and treatment of PDAC

🧠 #Glioblastoma (GBM) is the most frequent and aggressive brain #tumour, whose treatment has not changed in the last 25 years. 𝗥𝗲𝗮𝗰𝗵𝗚𝗟𝗜𝗢 project, funded by JTC 2022, works on approaches with drug loaded and tumour-targeted nanoparticles

15 MSCA postdoctoral EU-cofunded fellowships are available - #AECCTalent A unique opportunity for talented postdoctoral cancer researchers across the globe to carry out their research projects in one of the selected host cancer research centres in Spain.